Evidence map›Paper›PMID 27411063›Full record

ArticlePloS one2016

Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein.

Mark D Hicar, Xuemin Chen, Chidananda Sulli, Trevor Barnes, Jason Goodman, Hakimuddin Sojar, Bryan Briney, Jordan Willis, Valentine U Chukwuma, Spyros A Kalams and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Mark D HicarDepartments of Pediatrics, University at Buffalo, Buffalo, New York, United States of America.
Xuemin ChenDepartments of Pediatrics, Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Chidananda SulliIntegral Molecular, Inc., Philadelphia, Pennsylvania, United States of America.
Trevor BarnesIntegral Molecular, Inc., Philadelphia, Pennsylvania, United States of America.
Jason GoodmanIntegral Molecular, Inc., Philadelphia, Pennsylvania, United States of America.
Hakimuddin SojarDepartments of Pediatrics, University at Buffalo, Buffalo, New York, United States of America.
Bryan BrineyDepartments of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Jordan WillisThe Program in Chemical Biology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Valentine U ChukwumaDepartments of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Spyros A KalamsDepartments of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Benjamin J DoranzIntegral Molecular, Inc., Philadelphia, Pennsylvania, United States of America.
Paul SpearmanDepartments of Pediatrics, Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
James E CroweDepartments of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Vanderbilt University Medical Center · USIntegral Molecular (United States) · USUniversity at Buffalo, State University of New York · USChildren's Healthcare of Atlanta · USEmory University · US

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
Tennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI John Koethe · 2015 to 2026
$27.5M
VIROLOGY COREP30AI054999 · NIAID · VANDERBILT UNIVERSITY · PI D'AQUILA, RICHARD · 2003 to 2011
$10.3M
Clonal Analysis of the Human B Cell Response to HIVU01AI078407 · NIAID · VANDERBILT UNIVERSITY · PI CROWE, JAMES E · 2008 to 2012
$3.9M
The role of non-broadly neutralizing antibodies targeting gp41 structural epitopes in long term nonprogression of HIV infectionR01AI125119 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI HICAR, MARK DANIEL · 2016 to 2020
$2.0M
Antibodies Recognizing Quaternary Differences in HIV Envelope Glycoproteins (K08)K08AI083078 · NIAID · VANDERBILT UNIVERSITY · PI HICAR, MARK DANIEL · 2009 to 2013
$639k
High-throughput Epitope Mapping of Anti-Viral AntibodiesR43AI096936 · NIAID · INTEGRAL MOLECULAR · PI DORANZ, BENJAMIN J · 2011 to 2011
$242k
NIAID NIH HHS K08 AI083078NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI054999NIAID NIH HHS P30 AI110527NIAID NIH HHS R01 AI125119NIAID NIH HHS R43 AI096936NIAID NIH HHS U01 AI078407
6 · The paper itself

Abstract

Numerous broadly neutralizing antibodies (Abs) target epitopes that are formed or enhanced during mature HIV envelope formation (i.e. quaternary epitopes). Generally, it is thought that Env epitopes that induce broadly neutralizing Abs are difficult to access and poorly immunogenic because of the characteristic oligomerization, conformational flexibility, sequence diversity and extensive glycosylation of Env protein. To enhance for isolation of quaternary epitope-targeting Abs (QtAbs), we previously used HIV virus-like particles (VLPs) to bind B cells from long-term non-progressor subjects to identify a panel of monoclonal Abs. When expressed as recombinant full-length Abs, a subset of these novel Abs exhibited the binding profiles of QtAbs, as they either failed to bind to monomeric Env protein or showed much higher affinity for Env trimers and VLPs. These QtAbs represented a significant proportion of the B-cell response identified with VLPs. The Ab genes of these clones were highly mutated, but they did not neutralize common HIV strains. We sought to further define the epitopes targeted by these QtAbs. Competition-binding and mapping studies revealed these Abs targeted four separate epitopes; they also failed to compete for binding by Abs to known major neutralizing epitopes. Detailed epitope mapping studies revealed that two of the four epitopes were located in the gp41 subunit of Env. These QtAbs bound pre-fusion forms of antigen and showed differential binding kinetics depending on whether oligomers were produced as recombinant gp140 trimers or as full-length Env incorporated into VLPs. Antigenic regions within gp41 present unexpectedly diverse structural epitopes, including these QtAb epitopes, which may be targeted by the naturally occurring Ab response to HIV infection.

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingB-Lymphocytesenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesHIV Envelope Protein gp41HIV InfectionsHumansImmunodominant EpitopesProtein DomainsRecombinant ProteinsAntibodies, MonoclonalAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency Virusgp140 envelope protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp41Immunodominant EpitopesRecombinant Proteins

Identifiers

PMID27411063
PMCPMC4943599
OpenAlexW2469686116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.